Dina prover är till nytta

2021


Ianevski et al 2021: Patient-tailored design for selective co-inhibition of leukemic cell subpopulations. Science advances. https://doi.org/10.1126/sciadv.abe4038

Liu, Minxia el al 2021: S100 Calcium Binding Protein Family Members Associate With Poor Patient Outcome and Response to Proteasome Inhibition in Multiple Myeloma. Frontiers in Cell and Developmental Biology. https://www.frontiersin.org/articles/10.3389/fcell.2021.723016/full

Lundgren et al 2021: Somatic mutations in lymphocytes in patients with immune-mediated aplastic anemia. Leukemia. https://doi.org/10.1038/s41375-021-01231-3

Miettinen et al 2021: Aminopeptidase Expression in Multiple Myeloma Associates with Disease Progression and Sensitivity to Melflufen. Cancers. https://doi.org/10.3390/cancers13071527

Mäkelä et al 2021: Discovery of a Novel CIP2A Variant (NOCIVA) with Clinical Relevance in Predicting TKI Resistance in Myeloid Leukemias. Clin Cancer Res https://doi.org/10.1158/1078-0432.CCR-20-3679

2019


Douglas et al 2019: ERCC6L2 defines a novel entity within inherited acute myeloid leukemia. Blood. https://doi.org/10.1182/blood-2019-01-896233

Dufva et al 2019: Integrated drug profiling and CRISPR screening identify essential pathways for CAR T cell cytotoxicity. Blood. https://doi.org/10.1182/blood.2019002121

Hohtari et al 2019: Immune cell constitution in bone marrow microenvironment predicts outcome in adult ALL. Leukemia. https://doi.org/10.1038/s41375-018-0360-1

Mäkelä et al 2019: Arpp19 Promotes Myc and Cip2a Expression and Associates with Patient Relapse in Acute Myeloid Leukemia. Cancers, 11, 1774. https://doi.org/10.3390/cancers11111774

2018

Wartiovaara-Kautto et al 2018: Germline alterations in a consecutive series of acute myeloid leukemia. Leukemia 32;2282-2285. https://doi.org/10.1038/s41375-018-0049-5